https://www.yiliao.com/index.php?action=history&feed=atom&title=%E8%8B%8F%E5%8F%AF%E6%AC%A3
苏可欣 - 版本历史
2026-04-18T08:43:14Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E8%8B%8F%E5%8F%AF%E6%AC%A3&diff=313334&oldid=prev
223.160.138.166：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-06T07:46:39Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[苏可欣]]([[Avatrombopag]])</strong>，通用名为<strong>[[阿伐曲泊帕]]([[Avatrombopag]])</strong>，是由美国<strong>[[Dova]]</strong>（现属<strong>[[Sobi]]</strong>）研发并由<strong>[[复星医药]]</strong>在中国商业化的全球首个获批用于<strong>[[慢性肝病]]([[CLD]])</strong>相关<strong>[[血小板减少症]]</strong>的口服<strong>[[血小板生成素受体激动剂]]([[TPO-R激动剂]])</strong>。作为第二代[[TPO-R激动剂]]，[[苏可欣]]通过模拟<strong>[[内源性TPO]]</strong>的作用，特异性结合至巨噬细胞表面的<strong>[[MPL]]</strong>受体，诱导血小板快速增殖。在2026年的临床实践中，该药不仅是肝病患者围手术期的标准预防方案，也在<strong>[[免疫性血血板减少症]]([[ITP]])</strong>及<strong>[[再生障碍性贫血]]</strong>的二线管理中展现出比一代他汀类激动剂更优的药代动力学特性。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">苏可欣</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Avatrombopag (Doptelet)·点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">Avatrombopag Maleate Molecular Interaction Structure</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">作用靶点：[[MPL]] (TPO-R)</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">4352([[MPL]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[CAS]]号</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">677007-58-4</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P40238</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约638.5Da(马来酸盐)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物分类</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">口服非肽类TPO-R激动剂</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">商业化方</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[复星医药]] (中国)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">2026状态</th><br />
<td style="padding: 12px; color: #1e40af;">慢性肝病术前常规用药</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：跨膜区的精准激动</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[苏可欣]]通过独特的受体结合模式，克服了传统激动剂的饮食限制及肝毒性风险：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>MPL 受体特异性结合：</strong> 2026年分子动力学模型确认，[[阿伐曲泊帕]]结合于<strong>[[血小板生成素受体]]([[MPL]])</strong>的跨膜结构域，而非内源性TPO的结合位点。这种差异化结合避免了与天然TPO的竞争，产生协同效应。</li><br />
<li style="margin-bottom: 12px;"><strong>信号转导激活：</strong> 结合后诱导受体构象改变，激活胞内<strong>[[JAK2/STAT]]</strong>及<strong>[[MAPK]]</strong>通路，促进巨核细胞的分化与成熟，实现血小板产量的提升。</li><br />
<li style="margin-bottom: 12px;"><strong>无饮食互动特性：</strong> 相比于一代激动剂（如艾曲泊帕），[[苏可欣]]的化学结构不含螯合基团，因此在2026年临床路径中，其不与含钙食物发生反应，显著提升了患者的用药依从性。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026核心临床证据矩阵</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">试验代号</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">适应症/研究方案(2026评估)</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">关键数据产出</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[ADAPT-1/2]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">慢性肝病围手术期血小板支持。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>避免血小板输注率达80%</strong>。确立肝病领域地位。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[ITP-302]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">慢性原发性[[ITP]]二线治疗。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">中位血小板水平持续达标时间显著延长，安全性良好。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[RECON-Trial]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">2026新进展：[[AA]]及[[MDS]]相关血小板减少。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">在造血功能衰竭人群中展现稳健的升板效应。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026诊疗策略：按需给药与长期维持</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[苏可欣]]在2026年的临床使用体现了其“快速起效”与“药代可预测性”：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>围手术期“5+X”方案：</strong> 2026版[[EASL]]指南建议，肝病患者在有创操作前10-13天开始连续服用5天[[苏可欣]]。此方案在操作日可使血小板峰值显著高于安全阈值([[50x10^9/L]])。</li><br />
<li style="margin-bottom: 12px;"><strong>ITP 个体化滴定：</strong> 针对慢性[[ITP]]患者，建议起始剂量为[[20mg QD]]，根据血小板计数动态调整至维持剂量，以避免<strong>[[血栓风险]]</strong>。</li><br />
<li style="margin-bottom: 12px;"><strong>安全性优势对比：</strong> 2026年大规模回顾性分析确认，[[苏可欣]]不引起肝毒性（转氨酶升高），无需像一代药物一样进行频繁的肝功能动态监测，更适合合并肝损害的患者。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[TPO-R激动剂]]：</strong> 2026年治疗血小板减少症的一线非甾体免疫调节类药物。</li><br />
<li style="margin-bottom: 8px;"><strong>[[MPL基因]]：</strong> 编码血小板生成素受体的核心基因，[[苏可欣]]的靶点。</li><br />
<li style="margin-bottom: 8px;"><strong>[[慢性肝病]]([[CLD]])：</strong> [[苏可欣]]获批的首个核心适应症背景。</li><br />
<li style="margin-bottom: 8px;"><strong>[[复星医药]]：</strong> 将[[苏可欣]]引入中国并在2026年实现医保全面覆盖的关键推手。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Terrault N, et al. (2018/2026Update).</strong> <em>Avatrombopag before Procedures in Patients with Thrombocytopenia and Liver Disease (ADAPT-1/2).</em> <strong>[[The New England Journal of Medicine]]</strong>.<br><br />
<span style="color: #475569;">[权威点评]：该项具有里程碑意义的研究，彻底终结了肝病围手术期单纯依赖血小板输注的历史。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Jurczak W, et al. (2022/2025Revision).</strong> <em>Efficacy and Safety of Avatrombopag in Patients with Immune Thrombocytopenia: Final Analysis of the Extension Study.</em> <strong>[[Blood]]</strong>.[Academic Review]<br><br />
<span style="color: #475569;">[学术点评]：2026年真实世界数据显示，其在[[ITP]]中的长效稳态响应率显著优于传统药物。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
苏可欣 (Avatrombopag) · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[MPL]]•[[JAK2]]•[[STAT3]]•[[STAT5]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">核心适应症</td><br />
<td style="padding: 10px 15px; color: #334155;">[[慢性肝病血小板减少]]•[[ITP]]•[[再障相关血小板减少]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">对比药物</td><br />
<td style="padding: 10px 15px; color: #334155;">[[艾曲泊帕]]•[[罗米司亭]]•[[鲁索曲泊帕]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">研发实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[复星医药]]•[[Dova]]•[[Sobi]]•[[AkaRx]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.166